Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Nuance Pharma to Start China Phase III Trial of RSV Vaccine in Adults

publication date: Nov 14, 2022

Shanghai Nuance Pharma was approved to start a pivotal China Phase III clinical trial of MVA-BN RSV vaccine to prevent respiratory syncytial virus (RSV) in adults. In 2021, Nuance in-licensed China and Southeast Asia rights to the vaccine from Copenhagen’s Bavarian Nordic in a $225 million deal. The vaccine is aimed at older and/or immunocompromised adults. The China trial will be run as an arm of a large Bavarian Nordic Phase III trial that will enroll more than 20,000 patients in the US and Germany. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here